SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description

Login to view
Course Activities.

CME Live Virtual Conferences

Go Back

Franck Rahaghi, MD, MHS, FCCP
Chairman, Department of Pulmonary Medicine
Head, Pulmonary Education and Rehabilitation
Cleveland Clinic Florida
Weston, FL

Medical Writer
Josh Kilbridge, President
Kilbride Associates
San Francisco, CA

: Evolving Strategies of Care in Pulmonary Arterial Hypertension: Integrating the Data into Practice
Activity/Course #:
: RealCME910990
: Free
Release/Start Date:
: Sep 06 2018
Expiration Date:
: Sep 05 2019
: Primary Care Medicine
Target Audience:
: Primary Care Providers
: RealCME
Estimated Time To Complete CME Activity:
: 1.0 Hour
: 1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s) which includes 0.25 pharmacology hour(s)
Hardware/Software Requirements:
Program Summary
Pulmonary arterial hypertension (PAH) is a subgroup of pulmonary hypertension (PH) and a chronic, progressive condition characterized by abnormally high pressure in the pulmonary vasculature. PAH has previously been considered a rare disease, but evidence suggests a prevalence of about 15-50 cases per million. In the United States, about 1,000 new cases of PAH are diagnosed each year.

The prognosis of PAH has improved with the availability of newer therapies, but outcomes are dependent on early diagnosis and treatment. This activity utilizes segments of a presentation by the faculty recorded at the Emerging Challenges in Primary Care Live Virtual Symposium: 2018, to reinforce teaching points made during this program. This program will address recognizing the signs and symptoms of PAH, performing an appropriate diagnostic evaluation, current treatment paradigm, managing adverse medication events and when to refer to tertiary PH centers.

Learning Objectives
After completing this program participants should be able to:

1. Review the risk factors and classification of pulmonary hypertension (PH)
2. Discuss the appropriate diagnostic strategy for pulmonary arterial hypertension (PAH), including the roles of echocardiography, ventilation/perfusion (V/Q) scanning, and right heart catheterization (RHC)
3. Review current and emerging treatments for patients with PAH
4. Describe how to monitor patients with PAH for disease progression

Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education which includes 0.25 pharmacology hours.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosures are provided below.

Franck Rahaghi, MD, MHS, FCCP serves as a consultant, speaker and researcher for Actelion, Bayer, and Gilead. Dr. Rahaghi also serves as a consultant/speaker for United Therapeutics.

Contributing Faculty
Alexander Duarte, MD has no financial relationships to disclose.

Arunabh Talwar, MD, FCCP serves as a speaker for Boehringer Ingelheim. Dr. Talwar also serves on the advisory board for Genentech.

Activity Planning Committe
Josh Killbridge, Medical Writer, has no relationships to disclose.

Gregg Sherman, MD, has no relationships to disclose.

Michelle Frisch, MPH, has no relationships to disclose.

Sheila Lucas,CWEP, has no relationships to disclose.

Sandy Bihlmeyer, MEd, has no relationships to disclose.

Stephen Webber has no relationships to disclose.
Commercial Support
This educational activity is supported by an educational grant from Actelion Pharmaceuticals.